Articles tagged "Immunosuppression"

2020 American Transplant Congress
Early Tacrolimus-LCP Conversion Due to Adverse Effects in Pancreas Transplant Recipients Improves Tolerance But Not Graft Survival
J. L. Descourouez, M. R. Jorgenson, D. C. Felix, J. Wiegel, G. E. Leverson, D. A. Mandelbrot, R. R. Redfield, J. S. Odorico
UW Health, Madison, WI
*Purpose: Tacrolimus-LCP (LCPT) is an extended release formulation of tacrolimus which has been shown to have fewer adverse drug effects (ADE) than immediate release tacrolimus…
2020 American Transplant Congress
CMV, EBV and BKV Viremia Rate Varied Depending on the Timing of Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression and HLA-Sensitization (HS) Status in Kidney Transplant Patients (KTx Pts)
B. Shin, N. Ammerman, A. Vo, S. C. Jordan, M. Toyoda, S. Sethi
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Viral infections (VI) represent significant morbidity and mortality factors for KTx Pts. We previously showed more VI in BLT-treated Pts compared with CNI Pts…
2020 American Transplant Congress
Filgrastim Utilization Evaluation in Solid Organ Transplant Recipients
O. Witkowsky, L. Stanz, K. Schnelle
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Neutropenia occurs in up to 40% of kidney and liver transplant (txp) recipients and has been associated with higher mortality rates in liver txp.…
2020 American Transplant Congress
Belatacept Monthly Therapy: Transplant Recipients’ Experience
S. N. Little¹, É. N. Arsenault Knudsen², D. A. Mandelbrot¹
¹Transplant, University of Wisconsin Hospital and Clinics, Madison, WI, ²University of Wisconsin Hospital and Clinics, Madison, WI
*Purpose: While graft and patient outcomes with belatacept have been relatively well documented, the decision to use belatacept for kidney transplant recipients rests in part…
2020 American Transplant Congress
Belatacept versus Tacrolimus Combined with Antithymocyte Globulin in Kidney Transplantation
J. Goldman¹, A. Mitrokhin², B. Trivedi¹, V. Vidyasagar¹, N. Vadivel¹, N. Goes³, M. Hart¹
¹Swedish Medical Center, Seattle, WA, ²SUNY, Brooklyn, NY, ³Permanente Medical Group, Oakland, CA
*Purpose: Belatacept (BELA) used for maintenance immunosuppression (IS) after kidney transplant (KT) shows similar graft and patient survival, but improved allograft function, despite more rejection…
2020 American Transplant Congress
Depletional Induction Improves Kidney Graft and Patient Survival in Recipients with a Previous Liver Transplant in the United States
S. M. Riad¹, N. Lim¹, S. Jackson², A. Matas³, J. Lake¹
¹Medicine, University of Minnesota, Minneapolis, MN, ²Fairview Health Services, Minneapolis, MN, ³Surgery, University of Minnesota, Minneapolis, MN
*Purpose: Induction choices for kidney-after-liver transplant recipients are variable. We examined the impact of kidney induction types on kidney graft and patient survival in liver…
2020 American Transplant Congress
Dual and Opposite Costimulatory Targeting with a Novel Hybrid Protein Effectively Prevents Renal Warm Ischemia Reperfusion Injury in a Rat Bilateral Kidney Model
J. Guiteras¹, L. De Ramon¹, E. Crespo¹, N. Bolaños¹, P. Fontova¹, M. Jarque¹, A. Torija¹, O. Bestard², J. Grinyó², J. Torras²
¹Experimental Nephrology, IDIBELL, Hospitalet de Llobregat, Spain, ²Bellvitge University Hospital, Hospitalet de Llobregat, Spain
*Purpose: Many studies showed the CTLA4 effectiveness in the inhibition of CD28-CD80/86 costimulatory pathway in transplant and autoimmune diseases. Furthermore, the PD1-PDL1/2 interaction has been…
2020 American Transplant Congress
Torque Teno Virus for Risk Stratification of Graft Rejection and Infection in Kidney Transplant Recipients – A Prospective Observational Trial
K. Doberer, G. Böhmig, E. Puchhammer, G. Bond
Medical University Vienna, Vienna, Austria
*Purpose: The non-pathogenic and ubiquitous Torque Teno virus (TTV) is associated with immunosuppression in solid organ transplant recipients. This trial was designed to assess the…
2020 American Transplant Congress
Evaluation of Rejection, Infection, and Malignancy Outcomes in Elderly Liver Transplant Recipients Compared to a Younger Cohort
B. Almalki¹, K. Cunningham¹, C. D'Agostino¹, M. Kapugi¹, C. Kane¹, A. Novak¹, D. Ladner², J. Schulte¹
¹Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, ²Division of Transplant Surgery, Northwestern Memorial Hospital, Chicago, IL
*Purpose: Previous data has shown elderly liver transplant recipients (LTx) to be at a lower risk of acute rejection than younger recipients. As such, elderly…
2020 American Transplant Congress
Establishing an Induction Protocol for Long-Term Multilineage Mixed Chimerism in Rhesus Macaques
K. Bruestle¹, H. Sakai¹, F. Fredriksson¹, B. Piegari¹, D. Ekanayake-Alper¹, A. McLuckie², R. Ober², J. Weiner¹, A. Iuga³, S. M. Coley³, M. Sykes¹, A. Griesemer¹
¹Columbia Center for Translational Immunology, Columbia University, New York City, NY, ²Institute for Comparative Medicine, Columbia University, New York City, NY, ³Department of Pathology and Cell Biology, Columbia University, New York City, NY
*Purpose: Mixed chimerism (MC) induction via non-myeloablative conditioning and bone marrow transplantation (BMT) induces tolerance to solid organs. Our standard MC induction protocol in cynomologous…